The preclinical biotech startup, EraCal Therapeutics, which develops drugs using cutting-edge science to treat health and obesity issues, has joined the SFNV.

Switzerland, February 2021 – EraCal Therapeutics, a Swiss producer of biotechnology drugs using cutting-edge technology to treat metabolic syndrome, has joined the SFNV. The company is currently focusing on a pipeline of appetite suppressants to tackle obesity and its metabolic complications. Its lead molecule, Era-107, is an oral appetite suppressor with superior efficacy and safety profile, as demonstrated in three vertebrate species. EraCal is now preparing to carry out further toxicology studies ahead of first-in-human trials.

For more information:

E-mail : info@eracal.ch

Latest Members